Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Shares of Eli Lilly & Co. rose 3.38% to $1,062.19 Monday, on what proved to be an all-around grim trading session for the ...

Orforglipron is Eli Lilly’s weight-loss pill, and Bank of America expects it to enter the market in the second half of 2026 ...

Eli Lilly (NYSE: LLY) has outperformed the market over the past 5 years by 31.02% on an annualized basis producing an average annual return of 44.05%. Currently, Eli Lilly has a market capitalization ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

EXCLUSIVE: Eli Craig, the rising genre filmmaker who directed and co-wrote the cult horror comedy Tucker & Dale vs. Evil, has ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Pharmaceutical giant Eli Lilly (NYSE: LLY) will open a 44,000-square-foot life sciences facility in Philadelphia. The space will span the first and second floors 2300 Market Street, an eight-story, ...

Before Saturday’s snowstorm passed through the area, Seymour’s swim teams had already logged a productive day. Besides getting in pre- and post-meet workouts, the Owls dominated the six-team “S” Super ...